Stock XLSCF XLIE SCIE
Add to a list
To use this feature you must be a member
Log inSign up

Financials XLIE SCIE OTC Markets

Equities

XLSCF

CH0461929603

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for XLIE SCIE -.--% -.--%
04-23 Xlife Sciences Posts Higher FY23 Profit; Revenue Falls MT
02-29 Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 156.9 279
Enterprise Value (EV) 1 217.3 335.4
P/E ratio 14.9 x 24 x
Yield - -
Capitalization / Revenue 153 x 282 x
EV / Revenue 211 x 339 x
EV / EBITDA -42.9 x -76.5 x
EV / FCF 143,170,847 x -32,036,660 x
FCF Yield 0% -0%
Price to Book 0.67 x 1.04 x
Nbr of stocks (in thousands) 5,284 5,590
Reference price 2 29.70 49.90
Announcement Date 4/20/23 2/29/24
1CHF in Million2CHF
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales 1 0.5148 0.3968 0.8061 1.028 0.9884
EBITDA 1 -0.7652 -3.087 -5.201 -5.067 -4.384
EBIT 1 -0.7678 -3.093 -5.233 -20.98 -20.31
Operating Margin -149.14% -779.56% -649.21% -2,041.2% -2,054.3%
Earnings before Tax (EBT) 1 1.033 21.2 53.19 4.039 4.534
Net income 1 1.05 21.46 53.42 14.31 14.88
Net margin 203.99% 5,408.47% 6,627.06% 1,392.26% 1,505.34%
EPS 2 0.2851 3.602 8.660 1.996 2.079
Free Cash Flow - 2.597 -4.62 1.518 -10.47
FCF margin - 654.49% -573.2% 147.67% -1,059.29%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - 12.1% - 10.61% -
Dividend per Share - - - - -
Announcement Date 4/26/21 4/26/21 4/29/22 4/20/23 2/29/24
1CHF in Million2CHF
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 53.7 47.7 61.5 60.4 56.5
Net Cash position 1 - - - - -
Leverage (Debt/EBITDA) -70.19 x -15.45 x -11.83 x -11.92 x -12.88 x
Free Cash Flow - 2.6 -4.62 1.52 -10.5
ROE (net income / shareholders' equity) - 18.6% 23.7% 2.67% 2.64%
ROA (Net income/ Total Assets) - -1.14% -0.98% -2.7% -2.53%
Assets 1 - -1,886 -5,437 -529.5 -587.5
Book Value Per Share 2 28.00 31.30 41.80 44.50 48.00
Cash Flow per Share 2 0.7300 1.130 0.3900 0.0400 0.0400
Capex 1 0.02 0.03 0.16 0.02 0.01
Capex / Sales 4.84% 7.56% 19.3% 1.49% 1.41%
Announcement Date 4/26/21 4/26/21 4/29/22 4/20/23 2/29/24
1CHF in Million2CHF
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+16.59% 45.51B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-9.89% 38.52B
LONZA GROUP AG Stock Lonza Group AG
+38.08% 38.13B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+27.12% 30.74B
CELLTRION, INC. Stock Celltrion, Inc.
-8.64% 26.03B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.81% 25.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.08% 14.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.85% 12.73B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.19% 11.29B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. XLS Stock
  4. XLSCF Stock
  5. Financials XLIE SCIE